Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Viridian Therapeutics, Inc.

35 indications, side-by-side phase, drug & LoA

$16.35

+0.21 (+1.3%)

C 43Pipeline Score Overvalued Pharma · Commercial
Market Cap
1.78 B
EPS
-3.76
P/E Ratio
-
Value Trade
27.38 M
SEC Financials
Q1 2026

  • Dilution Risk

    25%

  • Revenue

    141.00 K

  • R&D Expenses

    77.63 M

  • Operating CF

    -119.65 M

  • Total Assets

    789.02 M

  • Total Liabilities

    153.01 M

  • Equity

    636.01 M

  • D/E Ratio

    12,345

-0.12 %
Week
19.64 %
1 Month
-38.84 %
3 Month
-41.18 %
6 Month
-3.9 %
5 Year
-99.17 %
All Time
Cash Data
Stable

  • Cash Position

    762.20 M

  • Monthly Burn

    39.88 M

  • Runway

    17.9 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    May 5, 2026
Overview
Volume
1.25 M
52 Week Range
13.18 - 34.29
% held by Insiders
7.18 %
% held by Institutions
101.15 %
Enterprise Value
1.20 B
Total Shares
95.40 M
Short %
16.91 %
Float Shares
86.34 M
Company Description
HQ: 221 CRESCENT STREET, WALTHAM, ...
Employees:252
https://www.viridiantherapeuti...

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 3 data readout example
VRDN-003 (subcutaneous anti-IGF-1R antibody) Chronic thyroid eye disease (TED)
Phase 3
—
Biologics
Ophthalmologic System
VRDN-003 (subcutaneous anti-IGF-1R antibody) Chronic thyroid eye disease (TED)
Phase 3
—
Biologics
Ophthalmologic System
VRDN-003 (subcutaneous anti-IGF-1R antibody) Chronic thyroid eye disease (TED)
Phase 3
—
Biologics
Ophthalmologic System
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
C43
Pipeline Score
$328M
Pipeline Value
Overvalued
Valuation Signal
3
Drugs Scored
0.2x
rNPV / MCap
Top 64%
Micro Cap
(rank 327 of 905)
Percentile Rank
Viridian Therapeutics, Inc. carries a moderate pipeline score (43/100), with $820M risk-adjusted pipeline value, led by Veligrotug in Thyroid Eye Disease (Phase 3).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
Veligrotug
Small molecule		Thyroid Eye DiseasePhase 3NCT0602105490% $446M COMPLETED 331 - -Jul 25, 2025 -Oct 23, 2025
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
VRDN-001
thyroid eye disease
Phase 3
2025-07-04
VRDN-001
thyroid eye disease
Phase 3
2025-07-04
VRDN-001
thyroid eye disease
Phase 3
2025-07-04
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in VRDN
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
VRDN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
VRDN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
VRDN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
VRDN Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
VRDN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-06-18 0.00 0 - - - - - -
2026-06-18 0.00 0 - - - - - -
2026-06-18 0.00 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Viridian Therapeutics, Inc. (VRDN) News & Alerts
-
Sunday, June 14, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How VRDN ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Thyroid Disorders #1 of 11 PHASE 3 VRDN-003
AMGN ZLAB IMVT
$11.1B 0.99 LEADER